Table 3: Selected genetic causes of obesity Navigation Tips: First column and header row are frozen for easy reference Scroll horizontally and vertically to view all data Hover over rows to highlight them Use compact mode to fit more content Hover over truncated text to see full content Setmelanotide, an MC4R agonist and first-in-class treatment for hereditary obesity Setmelanotide, (Imcivree), is an MC4R agonist discovered by Ipsen SA and developed by Rhythm Pharmaceuticals that has been approved in the US since 2020 for treatment of obesity due to deficiencies of POMC, PCSK1 or LEPR confirmed by genetic testing 15 and since 2022 for syndromic obesity due to Bardet-Biedl Syndrome, a rare genetic ciliopathy 34
Saline (0.9 percent NaCl) should be avoided because chloride competes for Cu(II) coordination and destabilizes the GHK-Cu chelate
Open Access REVIEW Glutamine transporters as effective targets in digestive system malignant tumor treatment 1 School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou, 510006, China 2 Department of Pharmacy, Tianjin Medical University General Hospital, Tianjin, 300070, China * Corresponding Author: LING WEI
Please contact your administrator for assistance
